Swiss pharma group Roche reported an increase in their global sales in the first half of the year by 5 percent, at a constant exchange rate, reaching CHF 22.9 billion due to the increased demand for cancer and autoimmune drugs, reports a press relese. According to Severin Schwan, Roche CEO, the good results are due to the performance of the cancer drugs, especially those against breast cancer, and the diagnostic division. The R&D division reported major progress as well both in Pharma and Diagnostic areas. )…) Considering the performance of Roche Group over the first six months, I am sure we will meet our targets for 2014,” stressed Schwan. For the current year, Roche forecasts an increase in sales of about 5 percent, for a constant exchange rate and higher dividends.
Israeli counter-terrorism expert Jonathan Fine: “I believe that Europe will also be confronted with other terrorist attacks”
ANRP case: Businessman Dorin Cocos makes new denunciation to DNA, admits to having coordinated bribes
President Iohannis in Berlin: Romania counts on Germany’s support to identify solutions to move forward toward Schengen accession
The Nine O’Clock Supplement
Nine O’Clock Announcements
5, Intrarea Armasului, District 1, Bucharest, Telephone: 317.71.36 / 317.71.35, Fax: 317.71.33 / 317.71.39
Nine O`clock Ads
Subscribe to RSS
Subscribe to RSS or enter you email to receive newsletter for news, articles, and updates about what's new.